Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug996 | Community interest message Wiki | 1.00 |
| drug1040 | Control message Wiki | 1.00 |
| drug1337 | Economic benefit message Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3562 | Self-interest message Wiki | 1.00 |
| drug2630 | Not bravery message Wiki | 1.00 |
| drug4097 | Trust in science message Wiki | 1.00 |
| drug287 | Anger message Wiki | 1.00 |
| drug2874 | Personal freedom message Wiki | 1.00 |
| drug1368 | Embarrassment message Wiki | 1.00 |
| drug1669 | Guilt message Wiki | 1.00 |
| drug1338 | Economic freedom message Wiki | 1.00 |
| drug523 | Baseline message Wiki | 1.00 |
| drug2616 | Normal Saline Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D055370 | Lung Injury NIH | 0.19 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of intravenous Sodium Nitrite Injection for treatment of patients infected with COVID-19 who develop lung injury and require mechanical ventilation.
Description: Proportion of study subjects who are alive and free of respiratory failure at Day 28
Measure: Survival with Unassisted Breathing Time: Day 28Description: Number of days alive without mechanical ventilation from start of study through Day 28
Measure: Survival without Mechanical Ventilation Time: Day 28Description: Number of days alive and not in the intensive care unit from start of study through Day 28.
Measure: Survival without Intensive Care Time: Day 28Description: Number of days alive and not in hospital from start of study through Day 28.
Measure: Survival without Hospitalization Time: Day 28Description: Alive on Day 28 and no use of ECMO therapy any time between start of study and Day 28.
Measure: Survival without ECMO Time: Day 28Description: Alive on Day 28
Measure: Survival Time: Day 28Description: Oxygenation index (PaO2/FIO2) at Day 14
Measure: Lung Status Time: Day 14Description: Blood urea nitrogen (BUN) at Day 14
Measure: Kidney Status (1) Time: Day 14Description: Creatinine at Day 14
Measure: Kidney Status (2) Time: Day 14Description: Liver function tests (ALT and AST) at Day 14
Measure: Liver Status Time: Day 14Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports